Anlon Healthcare IPO: A Comprehensive Guide for Indian Investors
Anlon Healthcare Ltd.’s initial public offering (IPO) has garnered significant attention from investors, with the issue being subscribed 4.33 times as of 11:15 a.m. on Friday. In this article, we will delve into the details of the IPO, including the subscription status, Grey Market Premium (GMP), and other key aspects that Indian investors should be aware of.
Subscription Status: A Positive Trend
The mainboard IPO, worth Rs 121.03 crore, comprises entirely a fresh issue of 1.33 crore shares. As of 11:15 a.m. on Friday, the subscription status was as follows:
- Qualified Institutions: 1.01 times
- Non-Institutional Buyers: 3.97 times
- Retail Investors: 29.80 times
The strong response from retail investors is a positive indication of the market’s sentiment towards the IPO. The subscription status is subject to change, and investors should keep a close eye on the updates.
Grey Market Premium (GMP): An Indicator of Listing Gains
The Grey Market Premium (GMP) of Anlon Healthcare was at Rs 5 as of 11:15 a.m. on Friday, indicating a 5.49% listing gain. The implied listing price of Rs 96 suggests that investors can expect a decent return on their investment. However, it is essential to note that GMP is not always an accurate indicator of the listing price, and investors should exercise caution.
Company Profile: Anlon Healthcare Ltd.
Anlon Healthcare Ltd., founded in 2013, is based in Rajkot, Gujarat. The company began its manufacturing operations in 2017 and is primarily engaged in the production of Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, and nutraceuticals. With a strong focus on research and development, Anlon Healthcare aims to establish itself as a leading player in the pharmaceutical industry.
IPO Details: Key Aspects for Investors
The following are the key details of the Anlon Healthcare IPO:
- IPO Size: Rs 121.03 crore
- Number of Shares: 1.33 crore
- Minimum Application Size: 164 shares (1 lot)
- Minimum Investment: Rs 14,924
- Maximum Investment: No limit
- Lead Manager: Interactive Financial Services Ltd.
- Registrar: Kfin Technologies Ltd.
Investors should carefully review the IPO details and assess their risk tolerance before making an investment decision.
Conclusion: A Promising Opportunity for Indian Investors
The Anlon Healthcare IPO presents a promising opportunity for Indian investors to participate in the growth story of the pharmaceutical industry. With a strong subscription status and a decent GMP, the issue is likely to attract significant attention from investors. However, it is crucial to approach the investment with caution and conduct thorough research before making a decision.
For more information on the Anlon Healthcare IPO and other investment opportunities, please visit our website and follow us on social media.
Click here to read more about the latest IPO news and updates.
Visit our investment guides to learn more about investing in the Indian stock market.